In last-year's difficult market, growth stocks were among the first to suffer. Why should we be confident about growth stocks? Moderna (NASDAQ: MRNA) went from zero product revenue prior to the pandemic to about $18 billion annually over the past two years.
InMode is Friday's IBD Stock Of The Day. The company says it's shrugging off recessionary concerns and INMD stock is smoothing out the wrinkles.
INMD is a medtech stock to buy the dip on